Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes

Journal of Cardiology

Volumn 55, Issue 3, 2010, Pages 303-308

  Ge, JunBo ^a   Kim, Young Jo ^b   Jang, Yang Soo ^c   Zhu, JunRen ^a   Marschner, Ian C ^d   Lam, William ^e  

^a FUDAN UNIVERSITY   (China)

^b Young Nam University Hospital   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d MACQUARIE UNIVERSITY   (Australia)

^e PFIZER INC   (United States)

Author keywords

Angiography; Cholesterol lowering drugs; Coronary artery disease; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; ENOXAPARIN; HEPARIN; MYOGLOBIN; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ASIA; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSPITAL ADMISSION; HUMAN; KOREA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON ST ELEVATION ACUTE CORONARY SYNDROME; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CHINA; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; HEPTANOIC ACIDS; HUMANS; KOREA; PREMEDICATION; PROSPECTIVE STUDIES; PYRROLES; TREATMENT OUTCOME;

EID: 77952104638     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.12.002     Document Type: Article

References (22)

1. World Health Organization. The world health report 2004. Changing history (2009), World Health Organization, Geneva. http://www.who.int/whr/2004/en/report04_en.pdf Available at: [accessed 17.09.09]
2. Wang Y., Mi J., Shan X.Y., Wang Q.J., and Ge K.Y. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 31 (2007) 177-188
3. Yoon S.J., Bae S.C., Lee S.I., Chang H., Jo H.S., Sung J.H., Park J.H., Lee J.Y., and Shin Y. Measuring the burden of disease in Korea. J Korean Med Sci 22 (2007) 518-523
4. World Health Organization. Cardiovascular diseases. Fact sheet 317 (2007, February), World Health Organization, Geneva. http://www.who.int/mediacentre/factsheets/fs317/en/print.html Available at: [accessed 17.09.09]
5. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., and Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
6. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., Thomason M.J., Mackness M.I., Charlton-Menys V., and Fuller J.H. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
7. Koren M.J., and Hunninghake D.B. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 44 (2004) 1772-1779
8. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., and Wenger N.K. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
9. Sever P.S., Dahlöf B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., and Östergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
10. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
11. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., and Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110 (2004) 674-678
12. Di Sciascio G. The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons. Fundam Clin Pharmacol 21 Suppl. 2 (2007) 41-43
13. Patti G., Pasceri V., Colonna G., Miglionico M., Fischetti D., Sardella G., Montinaro A., and Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49 (2007) 1272-1278
14. Di Sciascio G., Patti G., Pasceri V., Gaspardone A., Colonna G., and Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 54 (2009) 558-565
15. Briguori C., Visconti G., Focaccio A., Golia B., Chieffo A., Castelli A., Mussardo M., Montorfano M., Ricciardelli B., and Colombo A. Novel Approaches for Preventing or Limiting Events (NAPLES) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 54 (2009) 2157-2163
16. Thygesen K., Alpert J.S., and White H.D. Universal definition of myocardial infarction. Eur Heart J 28 (2007) 2525-2538
17. Woodward M., Huxley H., Lam T.H., Barzi F., Lawes C.M., and Ueshima H. A comparison of the associations between risk factors and cardiovascular disease in Asia and Australasia. Eur J Cardiovasc Prev Rehabil 12 (2005) 484-491
18. Liao J.K. Safety and efficacy of statins in Asians. Am J Cardiol 99 (2007) 410-414
19. Jia X.W., Fu X.H., Zhang J., Gu X.S., Fan W.Z., Wu W.L., Hao G.Z., Li S.Q., and Jiang Y.F. Intensive cholesterol lowering with statin improves the outcomes of percutaneous coronary intervention in patients with acute coronary syndrome. Chin Med J 122 (2009) 659-664
20. Patti G., Chello M., Pasceri V., Colonna D., Nusca A., Miglionico M., D'Ambrosio A., Covino E., and Di Sciascio G. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 48 (2006) 1560-1566
21. Patti G., Chello M., Candura D., Pasceri V., D'Ambrosio A., Covino E., and Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114 (2006) 1455-1461
22. Patti G., Nusca A., Chello M., Pasceri V., D'Ambrosio A., Vetrovec G.W., and Di Sciascio G. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 101 (2008) 279-285